Rodman & Renshaw analyst Elemer Piros initiated coverage of Tharimmune (THAR) with a Buy rating and $17 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read More on THAR: Tharimmune presents clinical data on TH104 for chronic pruritus Tharimmune granted patent for delivery of molecularly targeted therapeutics Tharimmune receives regulatory feedback from EMA for TH104 program Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting